Vizual Stocks works best vertically on mobile.
VizualStocks APIOperating KPI and segment definitions available for Lantheus Holdings (LNTH) through the VizualStocks API.
Sales of DEFINITY, Lantheus's injectable ultrasound-enhancing agent used to improve echocardiogram images in patients with suboptimal heart scans. It is part of the Precision Diagnostics product category.
definityRevenueRevenue from licensing Lantheus technology or product rights and royalties earned from partners that commercialize licensed products. This accounting-source category is separate from revenue generated by delivering Lantheus's physical products.
licenseAndRoyaltyRevenueSales of Lantheus diagnostic-imaging products other than the separately disclosed DEFINITY, Neuraceq and TechneLite lines. This historical residual included smaller nuclear-imaging products and largely disappears after the SPECT product portfolio was sold in January 2026.
otherPrecisionDiagnosticsRevenueResidual, if any, between Lantheus's separately reported product revenue plus license and royalty revenue and consolidated revenue. The company does not report this as a substantive revenue category, so the configured series is normally zero.
otherRevenueBySegmentRevenue from delivering Lantheus's physical imaging products, including PYLARIFY, DEFINITY and Neuraceq and, through 2025, TechneLite and related products. It excludes license and royalty revenue even when those arrangements involve the same broader product portfolio.
productRevenueSales of PYLARIFY, an F 18-labeled PET imaging agent that targets prostate-specific membrane antigen to help locate suspected metastatic or recurrent prostate cancer. PYLARIFY is Lantheus's principal Radiopharmaceutical Oncology product.
pylarifyRevenueRevenue from pharmaceutical and academic partners using Lantheus products in clinical trials, plus partner royalties and milestones and contract development and manufacturing work from Evergreen. It is a portfolio category rather than a single product line.
strategicPartnershipsAndOtherRevenueSales of TechneLite generators, which supplied technetium-99m used by radiopharmacies to prepare nuclear-imaging agents. Lantheus sold TechneLite and its related SPECT business to SHINE on January 1, 2026, so this is a discontinued product-revenue series after 2025.
techneliteRevenueCombined revenue from Lantheus's diagnostic-imaging portfolio, including DEFINITY and Neuraceq and, before its January 2026 sale, TechneLite and other SPECT products. The category helps clinicians find and follow disease rather than deliver radiotherapeutic treatment.
totalPrecisionDiagnosticsRevenueRevenue from Lantheus products used in the diagnosis and management of cancer, currently driven by the prostate-cancer imaging agent PYLARIFY. The category historically also included AZEDRA until Lantheus discontinued its production in the first quarter of 2024.
totalRadiopharmaceuticalOncologyRevenue